Compare Magna International Inc. Common Stock (MGA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magna International Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Magna International Inc. Common Stock trades at $64.38 (market cap $17.39B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Magna International Inc. Common Stock is far larger — about 4.6× Tango Therapeutics Inc.'s market cap, and Magna International Inc. Common Stock pays a 3.03% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magna International Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| MGA | TNGX | |
|---|---|---|
Market Cap | $17.39B | $3.75B |
Volume | 1,279,527 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $73.05 | $32.90 |
52-Week Low | $44.65 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.42B | $2.77B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magna International (MGA) trades at $65.31, up 2.75% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and trades at attractive valuations with P/E of 24.01 and P/S of 0.43. Recent news highlights margin expansion and international growth opportunities, while cash flow remains positive despite increased capital returns.
MGA presents a favorable risk-reward profile with analyst consensus target of $69.20 (5.9% upside) and 43% buy ratings. Key catalysts include Q3 2026 earnings on October 30 and continued margin improvement, though risks include flat auto production and potential tariff impacts on North American operations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Magna International Inc. Common Stock
Magna International Inc. is a Canada-based automotive supplier that designs, engineers, and manufactures vehicle systems and components, including body and chassis structures, seating, powertrain, and electronics, and provides complete-vehicle engineering and contract assembly, with manufacturing operations in 28 countries.
Read more on MGA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
